Marked response of a hypermutated acth-secreting pituitary carcinoma to ipilimumab and nivolumab

Keyphrases

• Nivolumab 100%
• Pituitary Carcinoma 100%
• Ipilimumab 100%
• Liver Metastasis 100%
• Acth 100%
• Hypermutated 100%
• Hypermutation 66%
• Effective Treatment 66%
• Temozolomide 66%
• Clinical Sequencing 66%
• Malignancy 33%
• Tumor 33%
• Tumor Volume 33%
• Liver 33%
• Treatment Response 33%
• Treatment Options 33%
• Metastasizing 33%
• Whole Exome Sequencing 33%
• Conventional Chemotherapy 33%
• Pituitary Tumor 33%
• Poor Prognosis 33%
• Older Women 33%
• Somatic Hypermutation 33%
• Alkylator 33%
• Response to Immunotherapy 33%
• Memorials 33%
• Combination Treatment 33%
• Capecitabine 33%
• Pituitary Adenoma 33%
• Molecular Assessment 33%
• Treatment-naïve 33%
• Molecular Alterations 33%
• Oncogenic Drivers 33%
• Intracranial Disease 33%
• Mutation Profiling 33%
• Tumor mutational Burden 33%
• ACTH-secreting pituitary Adenoma 33%
• Cancer Target 33%
• Temozolomide Resistant 33%

Medicine and Dentistry

• Ipilimumab 100%
• Temozolomide 100%
• Nivolumab 100%
• Liver Metastasis 100%
• Pituitary Cancer 100%
• Neoplasm 66%
• Immunotherapy 66%
• Effective Treatment 66%
• Malignant Neoplasm 33%
• Cancer 33%
• Carcinogenesis 33%
• Treatment Response 33%
• Exome Sequencing 33%
• Pituitary Tumour 33%
• Somatic Hypermutation 33%
• Somatics 33%
• Corticotropin 33%
• Pituitary Adenoma 33%
• Capecitabine 33%
• ACTH Secreting Adenoma 33%
• Diseases 33%
• Chemotherapy 33%
• Treatment Option 33%